A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults

Sponsor
Takeda (Industry)
Overall Status
Completed
CT.gov ID
NCT05064449
Collaborator
(none)
28
Enrollment
1
Location
2
Arms
1.5
Actual Duration (Months)
18.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main aim of this study is to check how itraconazole and mefenamic acid affect the way soticlestat is processed by the body.

The study will have 2 parts. Participants can only participate in one study part.

Part 1: Participants will check into the study clinic to receive soticlestat, four days later they will begin receiving itraconazole and will stay in the clinic for 11 more days, receiving soticlestat in combination with itraconazole on one of those days. Participants will be contacted about 8 days after leaving the clinic for follow-up.

Part 2: Participants will check into the study clinic to receive soticlestat, four days later they will begin receiving mefenamic acid and will stay in the clinic for 7 more days, receiving soticlestat in combination with mefenamic acid on one of those days.. Participants will be contacted about 9 days after leaving the clinic for follow-up.

Condition or DiseaseIntervention/TreatmentPhase
Phase 1

Detailed Description

The drug being tested in this study is called soticlestat (TAK-935). The study will evaluate the safety and tolerability of soticlestat when co-administered with either itraconazole or mefenamic acid in healthy participants.

The study will be conducted in 2 parts: Part 1 (drug-drug interaction [DDI] with itraconazole), Part 2 (DDI with mefenamic acid). The study will enroll approximately 28 participants. Participants will be enrolled into two parts (Part 1 and Part 2) to receive soticlestat along with adjunctive therapy itraconazole and mefenamic acid as:

  • Part 1: Soticlestat 300 mg + Itraconazole 200 mg

  • Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg (first dose only) and 250 mg (subsequent doses)

Both Parts 1 and 2 will have two period (Periods 1 and 2). In Period 1, participants will receive only soticlestat (study drug) and in Period 2, participants will receive study drug along with either itraconazole or mefenamic acid depending upon in which part they are in. The data will be collected and stored in electronic case report form (eCRF).

This single-center trial will be conducted in the United States. The overall duration of the study is approximately 52 days for participants in Part 1 (includes screening and follow-up), but 48 days for participants in Part 2 (including screening and follow-up). There will be follow up for all participants approximately 15 days after the last dose of soticlestat in each study part.

Study Design

Study Type:
Interventional
Actual Enrollment :
28 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
A Phase 1, Open-Label Study to Evaluate the Effect of Itraconazole and Mefenamic Acid on the Single-Dose Pharmacokinetic Profile of Soticlestat in Healthy Participants
Actual Study Start Date :
Oct 14, 2021
Actual Primary Completion Date :
Nov 21, 2021
Actual Study Completion Date :
Nov 30, 2021

Arms and Interventions

ArmIntervention/Treatment
Experimental: Part 1: Soticlestat 300 mg + Itraconazole 200 mg

Soticlestat 300 milligram (mg), tablets, orally, once on Day 1 in Period 1, followed by 4 days washout period, followed by itraconazole 200 mg solution, orally, once daily from Day 1 up to Day 11, further followed by soticlestat 300 mg tablet, orally along with itraconazole 200 mg solution, orally on the morning of Day in Period 2.

Drug: Soticlestat
Soticlestat tablets.
Other Names:
  • TAK-935
  • Drug: Itraconazole
    Itraconazole oral solution.

    Experimental: Part 2: Soticlestat 300 mg + Mefenamic Acid 500 mg

    Soticlestat 300 mg, tablets, orally, once on Day 1 in Period 1, followed by 4 days washout period, followed by single dose of mefenamic acid 500 mg capsule (first dose only), orally on the morning of Day 1 and 250 mg subsequent doses at every six hours up to Day 7 in Period 2, further followed by soticlestat 300 mg tablet, orally, followed by mefenamic acid 250 mg capsule, orally in morning of Day 2 in Period 2.

    Drug: Soticlestat
    Soticlestat tablets.
    Other Names:
  • TAK-935
  • Drug: Mefenamic acid
    Mefenamic acid capsule.

    Outcome Measures

    Primary Outcome Measures

    1. Parts 1 and 2: Cmax: Maximum Observed Plasma Concentration for Soticlestat [Parts 1, 2 (Period 1):Day 1 predose and multiple timepoints (up to 96 hours) postdose;Part 1 (Period 2) Day 5 predose and multiple timepoints (up to 168 hours) postdose; Part 2 (Period 2) Day 2 predose and multiple timepoints (up to 144 hours) postdose]

    2. Parts 1 and 2: AUC∞: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for Soticlestat [Parts 1, 2 (Period 1):Day 1 predose and multiple timepoints (up to 96 hours) postdose;Part 1 (Period 2) Day 5 predose and multiple timepoints (up to 168 hours) postdose; Part 2 (Period 2) Day 2 predose and multiple timepoints (up to 144 hours) postdose]

    3. Parts 1 and 2: AUClast: Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for Soticlestat [Parts 1, 2 (Period 1):Day 1 predose and multiple timepoints (up to 96 hours) postdose;Part 1 (Period 2) Day 5 predose and multiple timepoints (up to 168 hours) postdose; Part 2 (Period 2) Day 2 predose and multiple timepoints (up to 144 hours) postdose]

    4. Parts 1 and 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Soticlestat [Parts 1, 2 (Period 1):Day 1 predose and multiple timepoints (up to 96 hours) postdose;Part 1 (Period 2) Day 5 predose and multiple timepoints (up to 168 hours) postdose; Part 2 (Period 2) Day 2 predose and multiple timepoints (up to 144 hours) postdose]

    Secondary Outcome Measures

    1. Number of Participants Who Experience at Least 1 Treatment-Emergent Adverse Event (TEAE) [Baseline up to Day 52]

    2. Number of Participants Who Experience Clinically Significant Abnormal Values for Laboratory Evaluations [Baseline up to Day 52]

    3. Number of Participants Who Experience Clinically Significant Abnormal Values for Vital Signs [Baseline up to Day 52]

    4. Number of Participants Who Experience Clinically Significant Abnormal Values for Electrocardiogram (ECG) [Baseline up to Day 52]

    5. Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) [Baseline up to Day 52]

      The C-SSRS is an interview-based rating scale to systematically assess any suicidality, suicidal behavior, or suicidal ideation. Any suicidality is emergence of any suicidal ideation or suicidal behavior. Any suicidal behavior is indicated when response is "yes" for any these questions- actual attempt to suicide, engaged in non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts. Any suicidal ideation is indicated when response is "yes" for any of these questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years to 55 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Has body mass index (BMI) greater than or equal to (>=) 18.0 and less than or equal to (<=) 32.0 kilogram per meter square (kg/m^2) at screening.

    2. Continuous non-smoker who has not used nicotine-containing products for at least 90 days prior to the first dosing.

    3. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or electrocardiograms (ECGs), as deemed by the Investigator or designee.

    • Supine blood pressure is >=90/40 millimeter of mercury (mmHg) and <=140/90 mmHg at screening;

    • Supine pulse rate is >=45 beats per minute (bpm) and <=100 bpm at screening;

    • QT interval corrected for pulse rate using Fridericia's formula (QTcF) is <=450 millisecond (msec) (males) or <=470 msec (females) and ECG findings considered normal or not clinically significant by the Investigator or designee at screening;

    • Estimated creatinine clearance >=80 milliliter per minute (mL/min) at screening;

    • Liver function tests including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) <=1.5*the upper limit of normal (ULN) at screening and check-in.

    1. Able to swallow multiple tablets.
    Exclusion Criteria:
    1. Has history of any illness that, in the opinion of the Investigator or designee, might confound the results of the study or poses an additional risk to the participants by their participation in the study.

    2. Has history or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.

    3. Has history or presence of hypersensitivity or idiosyncratic reaction to the study drugs or related compounds.

    4. Unable to refrain from or anticipates the use of:

    • Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing. Thyroid hormone replacement medication may be permitted if the participant has been on the same stable dose for the immediate 3 months prior to first dosing.

    1. Has history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to the following: beer 354 milliliter (mL)/12 Ounce [oz], wine [118 mL/4 oz], or distilled spirits [29.5 mL/1 oz] per day).

    2. Consumes excessive amounts, defined as greater than 4 servings (1 serving is approximately equivalent to 120 mg of caffeine), of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.

    3. Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing and throughout the study.

    4. Donation of blood or significant blood loss within 56 days prior to the first dosing.

    5. Plasma donation within 7 days prior to the first dosing.

    6. Has participation in another clinical study within 30 days or 5 half-lives prior to the first dosing. The 30-day window or 5 half-lives will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1CelerionLincolnNebraskaUnited States68502

    Sponsors and Collaborators

    • Takeda

    Investigators

    • Study Director: Study Director, Takeda

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Takeda
    ClinicalTrials.gov Identifier:
    NCT05064449
    Other Study ID Numbers:
    • TAK-935-1007
    First Posted:
    Oct 1, 2021
    Last Update Posted:
    Dec 2, 2021
    Last Verified:
    Dec 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Takeda
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 2, 2021